Ligand/receptor-based chimeric antigen receptors: a promising alternative to conventional scFv designs in cancer immunotherapy

Transplantation and Cellular Therapy · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles